Other Reagents & Applications

APTIMA® for Chlamydia trachomatis and Neisseria gonorrhoeae
APTIMA® General Purpose Reagents (GPR)
APTIMA® Analyte Specific Reagents (ASR) for Trichomonas vaginalis
APTIMA® HPV
PCA3
Gene Fusions

Click on a highlighted title to read the PDF.

APTIMA® for Chlamydia trachomatis and Neisseria gonorrhoeae - Posters
Title Primary Author and Affiliation Poster - Where & When Presented
Four and a Half Year History of APTIMA® GC/CT Nucleic Acid Amplification Testing (NAAT) in Children Seen for Sexual Abuse Chapin; Rhode Island Hospital, Hasbro Children’s Hospital Poster 2010 CDC STD Prevention Conference
Sentinel Surveillance for Rectal Chlamydia and Gonorrhea in San Francisco Bernstein; San Francisco Dept. of Public Health Poster 2009 ISSTDR
Stability of Seeded Swab Specimens for the Detection of Chlamydia trachomatis in the Gen-Probe APTIMA Test Schachter; University of California, San Francisco Poster 2009 ISSTDR
Chlamydia and Gonorrhea Infections at the Time of a Positive RPR in STD Clinic Patients Philip; San Francisco Department of Public Health Poster 2009 ISSTDR
Performance of Nucleic Acid Amplification Tests (NAATs) for Chlamydia and Gonococcal Infections of the Oropharynx and Rectum Klausner; San Francisco DOH, San Francisco, CA Poster 2004 American Society of Microbiology Meeting
Evaluation of the APTIMA CT Assay as a Direct and Confirmatory Method for the Detection of Chlamydia trachomatis LeBar; Hospital Consolidated Services, Southfield, MI Poster 2004 Clinical Virology Meeting
Use of M4 Transport Medium for Detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) with the APTIMA Combo 2, APTIMA CT and APTIMA GC Assays LeBar; Hospital Consolidated Services, Southfield, MI Poster 2004 American Society of Microbiology Meeting
Use of the APTIMA Combo 2 Test for Chlamydia trachomatis and Neisseria gonorrhoeae in Pharyngeal and Rectal Specimens Ferrero; San Joaquin PH, Stockton, CA Poster 2003 American Society of Microbiology Meeting
Simultaneous Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in the APTIMA Combo 2 Assay by Testing Cervical Swabs Previously tested by LCx or ProbeTec Assays Chernesky; St. Joseph's Hospital, Hamilton, Canada Poster 2002 European Congress of Clinical Microbiology and Infectious Disease

 


APTIMA® General Purpose Reagents (GPR) - Posters
Title Primary Author and Affiliation Poster - Where & When Presented
Semi-Automated and Fully Automated Viral Transcription-Medicated Amplification Nucleic Acid Test Assay Development Using General Purpose Reagents
 Getman; Gen-Probe Incorporated, San Diego, CA
 Poster 2004 Clinical Virology Meeting


APTIMA® Analyte Specific Reagents (ASR) for Trichomonas vaginalis - Posters
Title Primary Author and Affiliation Poster - Where & When Presented
Comparison of Transcription-Mediated Amplification (TMA) and Polymerase Chain Reaction (PCR) Methods for Detection of Trichomonas vaginalis from SUN Study Patients Chapin; Rhode Island Hospital, The Miriam Hospital Poster 2010 CDC STD Prevention Conference
Detection of Trichomonas vaginalis (TV) in a Varied Patient Population Using APTIMA Trichomonas Analyte Specific Reagents (ASRS) Chapin; Rhode Island Hospital, The Miriam Hospital Poster 2009 ISSTDR
Analytical Performance of the APTIMA® Trichomonas Assay on the Automated TIGRIS® DTS® System Getman; Gen-Probe Incorporated, San Diego, CA Poster 2009 ISSTDR
Analytical Sensitivity of the Urine-Based APTIMA® Trichomonas vaginalis Molecular Assay Using the Automated TIGRIS® Platform Freeman; San Francisco Department of Public Health Poster 2009 ISSTDR
Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in Young Women in Kenya Using the Gen-Probe APTIMA™ Assays Moncada; University of California, San Francisco, Kenya Medical Research Institute Poster 2009 ISSTDR
Endocervical and Vaginal Specimens are Comparable for Detection of T. vaginalis Using Transcription-Mediated Amplification (TMA) Hobbs; University of North Carolina Poster 2009 ISSTDR
Clearance of Chlamydial Ribosomal RNA by APTIMA Combo 2® Testing in Women With Chlamydia Treated with Azithromycin Renault; Stanford University School of Medicine, Palo Alto, CA Poster 2009 ISSTDR
Evaluation of the Papanicolaou Stain Versus APTIMA® Trichomonas vaginalis Analyte Specific Reagents for the Detection of Trichomonas vaginalis from Cytyc® ThinPrep Vials Fuller; Wishard Health Services Indiana University, IN Poster 2007 American Society of Microbiology Meeting
Evaluation of Real-Time PCR and Transcription-Mediated Amplification for Detection of Trichomonas vaginalis in Urine Hobbs; The University of North Carolina at Chapel Hill, Chapel Hill, NC Poster 2006 American Society of Microbiology Meeting
Use of Gen-Probe APTIMA® Tests to Detect Multiple Etiologies of Urethritis and Cervicitis in Sexually Transmitted Disease (STD) Clinics Gaydos; The Johns Hopkins University, Baltimore, MD Poster 2006 American Society of Microbiology Meeting
Comparison of Cervical Samples to vaginal Samples for the Detection of Trichomonas vaginalis Using a GEN-PROBE Research Assay for rRNA Gaydos; The Johns Hopkins University, Baltimore, MD Poster 2005 American Society of Microbiology Meeting
Comparison between the research GEN-PROBE APTIMA formatted assay for rRNA (AMP-TV) and a real-time PCR, B-TUB FRET, for the detection of Trichomonas vaginalis Gaydos; The Johns Hopkins University, Baltimore, MD Poster 2005 American Society of Microbiology Meeting
Comparison of Transcription-Mediated Amplification, culture and PCR methods for detection of Trichomonas vaginalis Getman; Gen-Probe Incorporated, San Diego, CA Poster 2005 Scheveningen Molecular Meeting
Detection of Trichomonas vaginalis (TV) in Female Urine and Vaginal Specimens Using a Transcription-Mediated Amplification (TMA) Assay Martin; LSU Health Sciences Center and the Gulf South STI TM Cooperative Research Center, New Orleans, LA Poster 2005 International Society for Sexually Transmitted Diseases Research
Rapid Detection of Trichomonas vaginalis from Vaginal Specimens by Transcription-Mediated Amplification Sitay; Gen-Probe Incorporated, San Diego, CA Poster 2003 American Society of Microbiology Meeting


APTIMA® HPV
Title Primary Author and Affiliation Poster - Where & When Presented
Clinical Performance of the APTIMA HPV Assay for Dectection of E6/E7 mRNA from High-Risk HPV Types in Liquid Based Cytology Specimens Hill; Gen-Probe Incorporated, San Diego, CA Poster 2009 ISSTDR
Clinical Correlation of APTIMA® HPV Assay in Comparison with Hybrid Capture 2® Test in Cervical Cancer Screening Ratnam; Public Health Laboratory, Canada Poster 2009 ISSTDR
Analytical Performance of the APTIMA HPV Assay on the PANTHER Analyzer Worlock; Gen-Probe Incorporated, San Diego, CA Poster 2009 ISSTDR
Performance of APTIMA HPV Assay in Referral Population Getman; Gen-Probe Incorporate, San Diego, California Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
Evaluation of the APTIMA Cervical Specimen Collection and Transport Kit Nugent; Gen-Probe Incorporate, San Diego, California Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
Comparison of Three High-Risk HPV (HR-HPV) Tests on ASC Samples with Follow-up Schledemann: Odense University Hospital, Denmark Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
Performance of HPV E6/E7 mRNA and DNA Tests for the Detection of CIN or Worse: Results from a Multicentre Canadian Study Ratnam; Public Health Laboratory, St. John's, Canada Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
Results of the French APTIMA HPV Screening Evaluation (FASE Study) Monsonego; European Institute of the Cervix, Paris Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
Detection of HPV mRNA in Cytology Specimens with the APTIMA HPV HPV Assay Clad; Universitaets-Frauenklinik, Freiburg, Germany Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
Does RNA Testing Detect Clinically Significant HPV Infection? Cuschieri; Royal Infirmary of Edinburgh Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
HPV mRNA and p16INK4a as Triage Markers in Cervical Cytology Reuschenbach; University of Heidelberg, Heidelberg, Germany Abstract 2009, 25th International Papillomavirus Conference and Clinical Workshop (IPV)
Characterization of a Prototype Transcription-Mediated Amplification (TMA) Based Diagnostic Assay for Detection of HPV E6/E7 mRNA in LBC Media Kolk; Gen-Probe Incorporated, San Diego, CA Poster 2006 EUROGIN, Paris, France


PCA3
Title Primary Author and Affiliation Publication
Clinical Use of Urine PCA3 mRNA Testing. Shappell, S and Marks, L.  Urology Times. 2009. 37(10):40-42.
Urinary Prostate Cancer 3 Test: Toward the Age of Reason? Vlaeminck-Guillem, V et al.; Centre Hospitalier Lyon Sud, Pierre-Benite, France J.Urol. 2009. 8 July. In Press.
Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Chun, F, et al.; University Hospital Hamburg-Eppendorf, Hamburg, Germany European Urology.  2009 October; 56(4):583-752.
Prostate Cancer in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).

 Kirby, RS, Fitzpatrick, JM, Irani, J, The Prostate Centre, London, UK BJU Intl. 2009. Accepted for publication 2.09.
Rational Approach to Implementation of Prostate Cancer Antigen 3 into Clinical Care.

 Wang, R, et al.; University of Michigan, Ann Arbor, Michigan

 Cancer. 2009 Sep 1;115(17):3879-86.
New and Novel Markers for rostate Cancer Detection. Risk, M, Lin, D.; University of Washington Medical Center, Seattle, WA Current Urology Reports. 2009, 10:179-186.
New Markers and Multivariate Models for Prostate Cancer Detection. Stephan, C et al.; Universitätsmedizin Berlin, Berlin, Germany AntiCancer Research. 2009;29:2589-2600.
The Use of PCA3 in the Diagnosis of Prostate Cancer. Hessels, D, Schalken, J; University Hospital Nijmegen, The Netherlands Nature Reviews Urology. 2009;6(5):255-261.
PCA3 Urine mRNA Testing for Prostate Carcinoma: Patterns of Use by Community Urologists and Assay Performance in Reference Laboratory Setting. Shappell, SB et al.; Molecular Oncology Diagnostic Laboratory, Dallas, TX J Urol. 2009 Feb;73(2):363-8.
PCA3 Score Before Radical Prostatectomy Predicts Extracapsular Extension (ECE) and Tumor Volume. Whitman, EJ et al.; Walter Reed Army Medical Center, Washington, DC J Urol. 2008(180), 1975-1979.
Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. Marks, LS et al.; Geffen School of Medicine at UCLA, Los Angeles, CA Rev Urol. 2008, 10(3), 175-181
Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3. Ankerst, DP et al.; University of Texas Health Sciences Center, San Antonio, TX J Urol. 2008, 180(4), 1303-1308.
Clinical utility of prostate carcinoma molecular diagnostic tests. Shappell, SB; Mosaic Diagnostics, Dallas, TX Rev Urol. 2008, 10(1), 44-69.
Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy. Haese, A. et al.; University Clinic Hamburg, Germany Eur Urol. 2008(54), 1081-1088.
Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. van Gils, MP et al.; Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Prostate. 2008, 68(11), 1215-22.
PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. Nakanishi, H.; The University of Texas M. D. Anderson Cancer Center, Houston, TX. J Urol. 2008, 179, 1804-9.
PCA3: A molecular urine assay for predicting prostate biopsy outcome

Deras, IL et al.; Gen-Probe, Inc., San Diego, CA

J Urol. 2008, 179(4), 1587-92.
Newer potential biomarkers in prostate cancer. Wright, JL et al.; University of Washington School of Medicine, Seattle, WA Rev Urol. 2007, 9(4), 207-13.
A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Sokoll, LJ, et al.; Johns Hopkins Medical Institutions, Baltimore, MD Clin Chim Acta. 2008, 389(1-2), 1-6.
PROGENSA® PCA3 test for prostate cancer detection. de la Taille, A. ; Henri Mondor Hospital, Créteil, France Expert Rev Mol Diagn. 2007, 7(5), 491-7.
Molecular PCA3 diagnostics on prostatic fluid. van Gils, MP et al.; Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Prostate. 2007, 67(8), 881-7.
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Marks, LS et al.; Urological Sciences Research Foundation, Los Angeles, CA Urology. 2007, 69(3), 532-5.
Molecular markers for prostate cancer. Reynolds, MA et al.; Gen-Probe Incorporated, San Diego, CA Cancer Lett. 2007, 249(1), 5-13.
APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Groskopf, J et al.; Gen-Probe Incorporated, San Diego, CA Clin Chem. 2006, 52(6), 1089-95.


Gene Fusions
Title Primary Author and Affiliation Poster - Where & When Presented
Molecular tests for the detection of prostate tumor derived nucleic acids in peripheral blood Jost, M., Day, J., Slaughter, R., Groskopf, J., Rittenhouse, H., Koreckij, T., Gonzales, D., Kinnunen, M., Vessella, R., & Reynolds, M.; Gen-Probe Incorporated, San Diego, CA Poster 2009 AACR Annual Meeting in Denver, CO
TMPRSS2:ERG Gene Fusion Molecular Urine Test Correlates with Indicators of Prostate Cancer Aggressiveness Groskopf, J., Siddiqui, J., Sefton-Miller, L., Aubin, S. M., Blase, A., Varambally, S., Sakamoto, K., Fradet, Y., Schalken, J., Rittenhouse, H., & Chinnaiyan, A.; Gen-Probe Incorporated, San Diego, CA Poster 2009 - Presented at Tuscon Symposium
TMPRSS2:ERG Gene Fusion Molecular Urine Test Correlates with Indicators of Prostate Cancer Aggressiveness Audin, S. M., Williamsen, S., Hodge, P., Meinke, J., Siddiqui, J., Sefton-Miller, L., Silberstein, J., Christensen, K., Blase, A., Kashefi, C., Fradet, Y., Rittenhouse, H., Sakamoto, K., Chinnaiyan, A., & Groskopf, J.; Gen-Probe Incorproated, San Diego, CA Poster 2009 American Urological Association in Chicago, IL

 

*ASR (Analyte Specific Reagent): Analytical and performance characteristics are